Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Real-Time Price · USD

1.040

-0.050 (-4.59%)

Apr 1, 2025, 4:00 PM EDT - Market closed

Chemomab Therapeutics Employees

Chemomab Therapeutics had 20 employees as of December 31, 2021.

Employees

20

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$697,250

Market Cap

19.61M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2021	20	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CMMB News

5 days ago - Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease - Benzinga
5 days ago - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers - GlobeNewsWire
26 days ago - New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis - GlobeNewsWire
4 weeks ago - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
5 weeks ago - Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis - GlobeNewsWire
4 months ago - Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit - GlobeNewsWire
4 months ago - Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewsWire
7 months ago - Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire